- Stocks
- Healthcare
- NASDAQ: BBIO

Price (delayed)

$60.6

Market cap

$9.05B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.2

Enterprise value

$9.96B

BridgeBio Pharma's gross margin has increased by 7% YoY

BridgeBio Pharma's revenue has plunged by 79% YoY but it has increased by 6% from the previous quarter

The gross profit has plunged by 77% YoY but it has grown by 6% from the previous quarter

BBIO's debt has surged by 193% year-on-year and by 179% since the previous quarter

BBIO's net income has dropped by 79% year-on-year and by 16% since the previous quarter

What are the main financial stats of BBIO

Market
Valuations
Earnings

Shares outstanding

149.28M

Market cap

$9.05B

Enterprise value

$9.96B

Price to earnings (P/E)

N/A

Price to book (P/B)

N/A

Price to sales (P/S)

964.39

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

1,143.15

Revenue

$8.71M

EBIT

-$477.57M

EBITDA

-$473.12M

Free cash flow

-$471.41M

Per share
Balance sheet
Liquidity

EPS

-$4.2

Free cash flow per share

-$3.4

Book value per share

-$2.65

Revenue per share

$0.06

TBVPS

$7.89

Total assets

$1.09B

Total liabilities

$1.48B

Debt

$1.38B

Equity

-$395.29M

Working capital

$850.39M

Debt to equity

-3.5

Current ratio

9.98

Quick ratio

9.71

Net debt/EBITDA

-1.93

Margins
Efficiency
Dividend

EBITDA margin

-5,431.3%

Gross margin

100%

Net margin

-5,968.9%

Operating margin

-6,193.3%

Return on assets

-59.6%

Return on equity

-2,257.5%

Return on invested capital

-45.1%

Return on capital employed

-47.8%

Return on sales

-5,482.4%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the BridgeBio Pharma stock price performed over time

Intraday

-1.7%

1 week

2.4%

1 month

2.11%

1 year

97.52%

YTD

-14.78%

QTD

-0.59%

How have BridgeBio Pharma's revenue and profit performed over time

Revenue

$8.71M

Gross profit

$8.71M

Operating income

-$539.5M

Net income

-$519.95M

Gross margin

100%

Net margin

-5,968.9%

BridgeBio Pharma's revenue has plunged by 79% YoY but it has increased by 6% from the previous quarter

BBIO's net income has dropped by 79% year-on-year and by 16% since the previous quarter

The gross profit has plunged by 77% YoY but it has grown by 6% from the previous quarter

BBIO's operating income has dropped by 77% year-on-year and by 14% since the previous quarter

What is BridgeBio Pharma's growth rate over time

What is BridgeBio Pharma stock price valuation

P/E

N/A

P/B

N/A

P/S

964.39

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

1,143.15

BBIO's EPS has dropped by 60% year-on-year and by 11% since the previous quarter

BridgeBio Pharma's revenue has plunged by 79% YoY but it has increased by 6% from the previous quarter

The stock's price to sales (P/S) is 68% more than its last 4 quarters average of 573.4

How efficient is BridgeBio Pharma business performance

The ROIC has grown by 49% YoY and by 19% from the previous quarter

The ROA has contracted by 32% YoY and by 12% from the previous quarter

BBIO's ROS is down by 10% since the previous quarter

What is BBIO's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for BBIO.

How did BridgeBio Pharma financials performed over time

BBIO's total assets is 26% smaller than its total liabilities

BBIO's total liabilities has soared by 175% YoY and by 149% QoQ

BBIO's total assets has soared by 55% since the previous quarter and by 10% year-on-year

BBIO's debt has surged by 193% year-on-year and by 179% since the previous quarter

BBIO's debt to equity has dropped by 141% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.